Because glucagon lowers mTORC1 and stimulates AMPK (Baum et al., 2009; Welles et al., 2020) and ketogenesis (Pocai, 2012; Torres et al., 2019a), the simultaneous agonism of GLP-1R and glucagon receptors constitute a potential approach for ADPKD. The gene discussed is GCG; the disease is autosomal dominant polycystic kidney disease.